Compare Keurig Dr Pepper Inc. Common Stock (KDP) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keurig Dr Pepper Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Keurig Dr Pepper Inc. Common Stock trades at $33.6 (market cap $45.07B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Keurig Dr Pepper Inc. Common Stock is far larger — about 4× Repligen Corporation Common Stock's market cap, and Keurig Dr Pepper Inc. Common Stock pays a 2.78% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keurig Dr Pepper Inc. Common Stock for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| KDP | RGEN | |
|---|---|---|
Market Cap | $45.07B | $11.31B |
Volume | 9,868,301 | 1,216,919 |
Sector | Consumer Staples | Health |
52-Week High | $33.50 | $194.57 |
52-Week Low | $25.31 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $73.53B | $11.20B |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keurig Dr Pepper (KDP) trades at $32.66, down 0.27% today, with strong technical momentum showing bullish moving averages and key support at $32. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.57 beating expectations of $0.537, and maintains a healthy 49.39% gross margin. Recent news highlights the planned 2027 business split and beverage innovation pipeline as growth catalysts.
KDP presents a favorable investment case with 62% analyst buy ratings and a $37.75 consensus price target offering 15% upside. However, risks include elevated debt levels at 74.2% of market cap and potential execution challenges with the upcoming corporate restructuring. The stock's current valuation at 32.99 P/E requires continued earnings growth to justify further appreciation.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keurig Dr Pepper Inc. Common Stock
Keurig Dr Pepper produces and distributes coffee, soft drinks, juices, and other beverages. It also operates the Keurig single-serve coffee system.
Read more on KDP →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
